15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 23 firms covering Regeneron Pharmaceuticals Inc, 16 rate it Buy or better, 7 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $185.00 to $1000.00 (about 5.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $751.80 sits 8% above the current $695.49. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $13.21 next quarter toward $47.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS23 ratings
Moderate Buy
Strong Buy00%
Buy1670%
Hold730%
Sell00%
Strong Sell00%
Based on 23 analysts giving stock ratings to Regeneron Pharmaceuticals Inc.
As of Jul, 16 of 23 firms rate REGN a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
REGN EPS & revenue forecast
EPS · NEXT QUARTER
$13.21
Range $8.88 – $16.69 · 20 analysts · +12% YoY
Next period, 20 analysts expect Regeneron Pharmaceuticals Inc to earn $13.21 a share (range $8.88 – $16.69), versus $11.83 a year earlier. Full-year consensus is $45.85, growing to $47.40 the year after.
REVENUE · NEXT QUARTER
$4.2B
Range $3.7B – $4.6B · 20 analysts · +12% YoY
Revenue is expected to reach $4.2B (range $3.7B – $4.6B), +11.8% year-over-year. Full-year consensus is $15.9B, rising to $17.6B next year.
Top analysts covering Regeneron Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on REGN.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$995.00+43.1% to target
Overall win rate
52%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #167
Hold
$641.00-7.8% to target
Overall win rate
50%
+ Follow
#3
Matthew Harrison
Morgan Stanley · Rank #243
Hold
$730.00+5.0% to target
Overall win rate
44%
+ Follow
#4
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$185.00-73.4% to target
Overall win rate
39%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$856.00+23.1% to target
Overall win rate
41%
+ Follow
REGN stock forecast FAQ
What is REGN's average 12-month price target?+
The 15 analysts with a live target average $751.80 for Regeneron Pharmaceuticals Inc over the next 12 months, ranging from a $1000.00 high to a $185.00 low.
Is REGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 23 analyst ratings, 16 are Buy or Strong Buy, 7 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for REGN?+
The Street-high target is $1000.00 (Guggenheim), and the Street-low is $185.00 (Benchmark). The average of all 15 active targets is $751.80.
How many Wall Street analysts cover REGN?+
23 analysts have an active rating on Regeneron Pharmaceuticals Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering REGN?+
Among analysts who currently cover REGN, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $995.00 target.
What is Regeneron Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $13.21 per share (range $8.88 – $16.69) across 20 analysts. Full-year EPS is projected at $45.85, rising to $47.40 the following year.
How much revenue is Regeneron Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $4.2B (range $3.7B – $4.6B). Full-year revenue is projected at $15.9B, growing to $17.6B next year.
Have analysts been upgrading or downgrading REGN lately?+
As of Jul, 16 of 23 firms rate REGN a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their REGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
